Centene Corporation - Q1 2026 Earnings Analysis

Performance Highlights

Centene reported Q1 2026 total revenues of $49.9 billion, up from $46.6 billion in Q1 2025, with adjusted diluted EPS of $3.37 beating the prior-year comparable of $2.90 by 16%. GAAP net earnings attributable to Centene reached $1.541 billion, up from $1.311 billion, as earnings from operations expanded to $1.861 billion from $1.534 billion a year earlier.

The most critical operating driver was a meaningful improvement in Medicare segment gross margin, which surged to $1.554 billion from $1.204 billion in Q1 2025, reversing a prolonged drag from Medicare Advantage losses; Medicaid gross margin also grew to $1.618 billion from $1.432 billion, while Commercial gross margin declined to $2.358 billion from $2.542 billion, reflecting ongoing mix and pricing dynamics. Operating cash flow of $4.366 billion dwarfed the prior-year $1.510 billion, driven by favorable claims payable timing and a $1.0 billion Part D receivable sale generating $970 million in proceeds.

Management Outlook and Forward Catalysts

Management deployed $1.029 billion to repurchase 2027 Senior Notes, reducing total debt to $16.4 billion and signaling a deliberate transition from leverage reduction to capital flexibility, supported by the Board expanding the senior note repurchase program by $1.0 billion in February 2026. The absence of a Medicare Advantage premium deficiency reserve in 2026, compared to the $270 million reserve recorded in Q1 2025, underscores management's confidence in Medicare Advantage contract year pricing adequacy.

The central investor debate heading into Q2 centers on whether Medicare Advantage margin recovery is durable as cost-sharing progresses through the year, and whether Medicaid rates keep pace with utilization following redetermination-driven membership shifts. Bulls will focus on the $1.194 billion favorable prior-year claims development and the strong cash build, while bears will monitor Commercial segment gross margin compression, the pending Magellan Health divestiture, and the unresolved federal securities class action filed in July 2025.